

MD Anderson Ovarian SPORE publications – 2018

1. Antony J, Zanini E, Kelly Z, Tan TZ, Karali E, Alomary M, Jung Y, Nixon K, Cunnea P, Fotopoulou C, Paterson A, Roy-Nawathe S, Mills GB, Huang RY, Thiery JP, Gabra H, Recchi C. **The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.** EMBO Rep. 2018 Aug;19(8):e45670. doi: 10.15252/embr.201745670. Epub 2018 Jun 15. PMID: 29907679
2. Armbruster S, Coleman RL, Rauh-Hain JA. **Management and Treatment of Recurrent Epithelial Ovarian Cancer.** Hematol Oncol Clin North Am. 2018 Dec;32(6):965-982. doi: 10.1016/j.hoc.2018.07.005. PMID: 30390768 Review.
3. Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, Soliman PT. **Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration.** Gynecol Oncol. 2018 Jun;149(3):484-490. doi: 10.1016/j.ygyno.2018.03.054. Epub 2018 Apr 2. PMID: 29622276
4. Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmouh L, Sood AK, Cole SW, Slavich GM, Lutgendorf SK. **Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.** Cancer. 2018 Aug;124(16):3401-3408. doi: 10.1002/cncr.31570. Epub 2018 Jun 15. PMID: 29905941
5. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R. **A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.** Cancer Cell. 2018 Apr 9;33(4):690-705.e9. doi: 10.1016/j.ccell.2018.03.014. Epub 2018 Apr 2. PMID: 29622464
6. Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, Han HD, Park YM. **CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.** Cancer Res. 2018 Nov 1;78(21):6247-6256. doi: 10.1158/0008-5472.CAN-17-3871. Epub 2018 Aug 16. PMID: 30115698
7. Cao Y, Jiang Y, Lin X, Liu J, Lu T, Cheng W, Yan F. **Dynamic Prediction of Outcome for Patients With Ovarian Cancer: Application of a Joint Model for Longitudinal Cancer Antigen 125 Values.** Int J Gynecol Cancer. 2018 Jan;28(1):85-91. doi: 10.1097/IGC.0000000000001134. PMID: 29135568
8. Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL. **Metastatic gynecologic malignancies: advances in treatment and management.** Clin Exp Metastasis. 2018 Aug;35(5-6):521-533. doi: 10.1007/s10585-018-9889-7. Epub 2018 Jun 21. PMID: 29931499 Review.
9. Chang CC, Su KM, Lu KH, Lin CK, Wang PH, Li HY, Wang ML, Lin CK, Yu MH, Chang CM. **Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis.** Int J Mol Sci. 2018 Oct 24;19(11):3311. doi: 10.3390/ijms19113311. PMID: 30356023
10. Colombo I, Kurnit KC, Westin SN, Oza AM. **Moving From Mutation to Actionability.** Am Soc Clin Oncol Educ Book. 2018 May 23;38:495-503. doi: 10.1200/EDBK_199665. PMID: 30231353 Review.
11. Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. **Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.** Ther Adv Med Oncol. 2018 Jun 22;10:1758835918778483. doi: 10.1177/1758835918778483. eCollection 2018. PMID: 29977351 Review.
12. Dal Molin GZ, Westin SN, Coleman RL. **Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.** Future Oncol. 2018 Dec;14(30):3101-3110. doi: 10.2217/fo-2018-0215. Epub 2018 Aug 14. PMID: 30105925 Review.

13. Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W; Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Jung AY, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, du Bois A, Harter P, Schwaab I, Karlan BY, Lester J, Orsulic S, Rimel BJ, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MAT, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LCV, Kopperud RK, Bjorge L, Kiemeny LA, Massuger LFAG, Pejovic T, Bruegl A, Cook LS, Le ND, Swererton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzylowska A, Rzepecka IK, Webb PM; Ovarian Cancer Association Consortium. **Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.** *Br J Cancer.* 2018 Apr;118(8):1123-1129. doi: 10.1038/s41416-018-0011-3. Epub 2018 Mar 20. PMID: 29555990
14. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. **When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System.** *Int J Gynecol Cancer.* 2018 Oct;28(8):1485-1490. doi: 10.1097/IGC.0000000000001329. PMID: 30036226
15. Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J, Aben KKH, Anton-Culver H, Antonenkova N, Bandera EV, Bean YT, Beckmann MW, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Hogdall CK, Høgdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Jung AY, Karlan BY, Kellar M, Kiemeny LA, Kiong Lim B, Kjaer SK, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lele S, Lester J, Levine DA, Li Z, Liang D, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LFAG, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Odunsi K, Olson SH, Orlow I, Orsulic S, Paul J, Pejovic T, Pelttari LM, Permuth JB, Pike MC, Poole EM, Rosen B, Rossing MA, Rothstein JH, Runnebaum IB, Rzepecka IK, Schernhammer E, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Tangen IL, Teo SH, Terry KL, Thompson PJ, Thomsen L, Tworoger SS, van Altena AM, Vergote I, Vestheim Thomsen LC, Vierkant RA, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu AH, Wu X, Xiang YB, Yang H, Zheng W, Ziogas A, Lee AW, Pearce CL, Berchuck A, Schildkraut JM, Ramus SJ, Monteiro ANA, Narod SA, Sellers TA, Gayther SA, Kelemen LE, Chenevix-Trench G, Risch HA, Pharoah PDP, Goode EL, Phelan CM. **Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.** *PLoS One.* 2018 Jul 6;13(7):e0197561. doi: 10.1371/journal.pone.0197561. eCollection 2018. PMID: 29979793
16. Elias KM, Guo J, Bast RC Jr. **Early Detection of Ovarian Cancer.** *Hematol Oncol Clin North Am.* 2018 Dec;32(6):903-914. doi: 10.1016/j.hoc.2018.07.003. Epub 2018 Sep 28. PMID: 30390764 Review.
17. Engel BJ, Gammon ST, Chaudhari R, Lu Z, Pisaneschi F, Yang H, Ornelas A, Yan V, Kelderhouse L, Najjar AM, Tong WP, Zhang S, Piwnica-Worms D, Bast RC Jr, Millward SW. **Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT.** *Bioconjug Chem.* 2018 Sep 19;29(9):3180-3195. doi: 10.1021/acs.bioconjchem.8b00514. Epub 2018 Aug 31. PMID: 30168713
18. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. **Laparoscopic Surgical Algorithm to Triage the Timing of Tumor**

- Reductive Surgery in Advanced Ovarian Cancer.** *Obstet Gynecol.* 2018 Sep;132(3):545-554. doi: 10.1097/AOG.0000000000002796. PMID: 30095787
19. Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK. **ADH1B promotes mesothelial clearance and ovarian cancer infiltration.** *Oncotarget.* 2018 May 18;9(38):25115-25126. doi: 10.18632/oncotarget.25344. eCollection 2018 May 18. PMID: 29861857
 20. Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. **FABP4 as a key determinant of metastatic potential of ovarian cancer.** *Nat Commun.* 2018 Jul 26;9(1):2923. doi: 10.1038/s41467-018-04987-y. PMID: 30050129
 21. Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. **LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.** *Cancer Res.* 2018 Apr 15;78(8):1923-1934. doi: 10.1158/0008-5472.CAN-17-1624. Epub 2018 Jan 31. PMID: 29386184
 22. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. **Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.** *Gynecol Oncol.* 2018 Dec;151(3):428-432. doi: 10.1016/j.ygyno.2018.10.017. Epub 2018 Oct 23. PMID: 30366647
 23. Hillman RT, Celestino J, Terranova C, Beird HC, Gumbs C, Little L, Nguyen T, Thornton R, Tippen S, Zhang J, Lu KH, Gershenson DM, Rai K, Broaddus RR, Futreal PA. **KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary.** *Nat Commun.* 2018 Jun 27;9(1):2496. doi: 10.1038/s41467-018-04950-x. PMID: 29950560
 24. Hillman RT, Chisholm GB, Lu KH, Futreal PA. **Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.** *J Natl Cancer Inst.* 2018 Mar 1;110(3):265-72. doi: 10.1093/jnci/djx176. PMID: 29584920
 25. Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. **Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.** *Gynecol Oncol.* 2018 Dec;151(3):407-413. doi: 10.1016/j.ygyno.2018.10.008. Epub 2018 Oct 24. PMID: 30366646
 26. Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao B. **Bone protection by inhibition of microRNA-182.** *Nat Commun.* 2018 Oct 5;9(1):4108. doi: 10.1038/s41467-018-06446-0. PMID: 30291236
 27. Jeong BY, C7ho KH, Jeong KJ, Park YY, Kim JM, Rha SY, Park CG, Mills GB, Cheong JH, Lee HY. **Rab25 augments cancer cell invasiveness through a β 1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin.** *Exp Mol Med.* 2018 Jan 26;50(1):e435. doi: 10.1038/emm.2017.248. PMID: 29371698
 28. Johnson C, Jazaeri AA. **Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes.** *Clin Ther.* 2018 Mar;40(3):389-394. doi: 10.1016/j.clinthera.2018.02.011. Epub 2018 Mar 5. PMID: 29519715
 29. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C; Cancer Genome Atlas Research Network, Rättsch G [Sood AK]. **Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.** *Cancer Cell.* 2018 Aug 13;34(2):211-224.e6. doi: 10.1016/j.ccell.2018.07.001. Epub 2018 Aug 2. PMID: 30078747
 30. Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. **Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.** *EBioMedicine.* 2018 Dec;38:100-112. doi: 10.1016/j.ebiom.2018.11.004. Epub 2018 Nov 25. PMID: 30487062
 31. Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I,

- Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, Odunsi K, Goodman MT, Shvetsov YB, Thompson PJ, Wilkens LR, Dörk T, Antonenkova N, Bogdanova N, Hillemanns P, Runnebaum IB, du Bois A, Harter P, Heitz F, Schwaab I, Butzow R, Pelttari LM, Nevanlinna H, Modugno F, Edwards RP, Kelley JL, Ness RB, Karlan BY, Lester J, Orsulic S, Walsh C, Kjaer SK, Jensen A, Cunningham JM, Vierkant RA, Giles GG, Bruinsma F, Southey MC, Hildebrandt MAT, Liang D, Lu K, Wu X, Sellers TA, Levine DA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Tworoger SS, Poole EM, Bandera EV, Olson SH, Orlow I, Vestrheim Thomsen LC, Bjorge L, Krakstad C, Tangen IL, Kiemenev LA, Aben KKH, Massuger LFAG, van Altena AM, Pejovic T, Bean Y, Kellar M, Cook LS, Le ND, Brooks-Wilson A, Gronwald J, Cybulski C, Jakubowska A, Lubiński J, Wentzensen N, Brinton LA, Lissowska J, Hogdall E, Engelholm SA, Hogdall C, Lundvall L, Nedergaard L, Pharoah PDP, Dicks E, Song H, Tyrer JP, McNeish I, Siddiqui N, Carty K, Glasspool R, Paul J, Campbell IG, Eccles D, Whittemore AS, McGuire V, Rothstein JH, Sieh W, Narod SA, Phelan CM, McLaughlin JR, Risch HA, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Gentry-Maharaj A, Ramus SJ, Wu AH, Pearce CL, Lee AW, Pike MC, Kupryjanczyk J, Podgorska A, Plisiecka-Halasa J, Sawicki W, Goode EL, Berchuck A; Ovarian Cancer Association Consortium. **rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.** *Int J Mol Sci.* 2018 Aug 21;19(9):2473. doi: 10.3390/ijms19092473. PMID: 30134598
32. Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, Park YY, Lee JW, Kang TH, Jung ID, Shin BC, Ahn HJ, Lee YJ, Sood AK, Han HD, Park YM. **Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.** *Drug Deliv.* 2018 Nov;25(1):1394-1402. doi: 10.1080/10717544.2018.1480672. PMID: 29890852
33. Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr. **Cell Origins of High-Grade Serous Ovarian Cancer.** *Cancers (Basel).* 2018 Nov 12;10(11):433. doi: 10.3390/cancers10110433. PMID: 30424539 Review.
34. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I; Cancer Genome Atlas Research Network, Monnat RJ Jr, Xiao Y, Wang C. **Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.** *Cell Rep.* 2018 Apr 3;23(1):239-254.e6. doi: 10.1016/j.celrep.2018.03.076. PMID: 29617664
35. Kuppa SS, Jia W, Liu S, Nguyen H, Smyth SS, Mills GB, Dobbin KK, Hardman WJ, Murph MM. **Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.** *Cancer Lett.* 2018 Sep 28;432:84-92. doi: 10.1016/j.canlet.2018.05.037. Epub 2018 May 31. PMID: 29859298
36. Kurnit KC, Coleman RL, Westin SN. **Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.** *Curr Treat Options Oncol.* 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7. PMID: 30535808 Review.
37. Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. **Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.** *J Clin Invest.* 2018 Feb 1;128(2):589-606. doi: 10.1172/JCI95200. Epub 2017 Dec 18. PMID: 29251630
38. Lewis KE, Lu KH, Klimczak AM, Mok SC. **Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.** *Cancers (Basel).* 2018 Feb 21;10(2):57. doi: 10.3390/cancers10020057. PMID: 29466291 Review.
39. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC Jr, Fu S, Hu W, Sood AK. **Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.** *Front Oncol.* 2018 Feb 9;8:9. doi: 10.3389/fonc.2018.00009. eCollection 2018. PMID: 29456965

40. Lu KH. **Screening for Ovarian Cancer in Asymptomatic Women.** JAMA. 2018 Feb 13;319(6):557-558. doi: 10.1001/jama.2017.21894. PMID: 29450509 No abstract available.
41. Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CV. **MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.** Cancer Res. 2018 Jan 1;78(1):64-74. doi: 10.1158/0008-5472.CAN-17-0815. Epub 2017 Nov 27. PMID: 29180471
42. Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW. **Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.** Cancer. 2018 Feb 1;124(3):580-586. doi: 10.1002/cncr.31078. Epub 2017 Nov 7. PMID: 29112229
43. Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC Jr. **Screening for ovarian cancer: imaging challenges and opportunities for improvement.** Ultrasound Obstet Gynecol. 2018 Mar;51(3):293-303. doi: 10.1002/uog.17557. PMID: 28639753
44. Matsuo K, Machida H, Grubbs BH, Sood AK, Gershenson DM. **Trends of low-grade serous ovarian carcinoma in the United States.** J Gynecol Oncol. 2018 Jan;29(1):e15. doi: 10.3802/jgo.2018.29.e15. PMID: 29185273 No abstract available.
45. Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM. **Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.** J Surg Oncol. 2018 Feb;117(2):236-244. doi: 10.1002/jso.24801. Epub 2017 Aug 8. PMID: 28787528
46. Meyer LA, He W, Sun CC, Zhao H, Wright AA, Suidan RS, Dottino J, Alejandro Rauh-Hain J, Lu KH, Giordano SH. **Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.** Gynecol Oncol. 2018 Sep;150(3):451-459. doi: 10.1016/j.ygyno.2018.06.020. Epub 2018 Jun 29. PMID: 29961559
47. Meyer LA, Lasala J, Iniesta MD, Nick AM, Munsell MF, Shi Q, Wang XS, Cain KE, Lu KH, Ramirez PT. **Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes.** Obstet Gynecol. 2018 Aug;132(2):281-290. doi: 10.1097/AOG.0000000000002735. PMID: 29995737
48. Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK. **Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).** Oncogene. 2018 Feb 8;37(6):722-731. doi: 10.1038/onc.2017.348. Epub 2017 Oct 23. PMID: 29059175
49. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. **ATP11B mediates platinum resistance in ovarian cancer.** J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. PMID: 29809169 No abstract available.
50. Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH. **Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.** Gynecol Oncol. 2018 Jul;150(1):79-84. doi: 10.1016/j.ygyno.2018.04.564. Epub 2018 May 4. PMID: 29735278 Clinical Trial.
51. Peng G, Mills GB. **Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1.** Clin Cancer Res. 2018 Feb 1;24(3):508-510. doi: 10.1158/1078-0432.CCR-17-3022. Epub 2017 Nov 30. PMID: 29191971
52. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ, McGuffog L, Parsons MT, Leslie G, Aalfs CM, Abugattas J, Adlard J, Agata S, Aittomäki K, Andrews L, Andrulis IL, Arason A, Arnold N, Arun BK, Asseryanis E, Auerbach L, Azzollini J,

- Balmaña J, Barile M, Barkardottir RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR, Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caldes T, Caliebe A, Caligo MA, Campbell I, Caputo SM, Chiquette J, Chung WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K, de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM, Velazquez C, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H, Ejlertsen B; EMBRACE, Engel C, Engert S, Evans DG, Faivre L, Feliubadaló L, Ferrer SF, Foretova L, Fowler J, Frost D, Galvão HCR, Ganz PA, Garber J, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Gerdes AM, Gesta P, Giannini G, Giraud S, Glendon G, Godwin AK, Greene MH, Gronwald J, Gutierrez-Barrera A, Hahnen E, Hauke J; HEBON, Henderson A, Hentschel J, Hogervorst FBL, Honisch E, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Vijai J, Kaczmarek K, Karlan BY, Kast K, Investigators K, Kim SW, Konstantopoulou I, Korach J, Laitman Y, Lasa A, Lasset C, Lázaro C, Lee A, Lee MH, Lester J, Lesueur F, Liljegren A, Lindor NM, Longy M, Loud JT, Lu KH, Lubinski J, Machackova E, Manoukian S, Mari V, Martínez-Bouzas C, Matrai Z, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Mickys U, Miller A, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Neuhausen SL, Nevanlinna H, Ngeow J, Nguyen HP, Niederacher D, Nielsen HR, Nielsen FC, Nussbaum RL, Offit K, Öfverholm A, Ong KR, Osorio A, Papi L, Papp J, Pasini B, Pedersen IS, Peixoto A, Peruga N, Peterlongo P, Pohl E, Pradhan N, Prajzandanc K, Prieur F, Pujol P, Radice P, Ramus SJ, Rantala J, Rashid MU, Rhiem K, Robson M, Rodriguez GC, Rogers MT, Rudaitis V, Schmidt AY, Schmutzler RK, Senter L, Shah PD, Sharma P, Side LE, Simard J, Singer CF, Skytte AB, Slavin TP, Snape K, Sobol H, Southey M, Steele L, Steinemann D, Sukiennicki G, Sutter C, Szabo CI, Tan YY, Teixeira MR, Terry MB, Teulé A, Thomas A, Thull DL, Tischkowitz M, Tognazzo S, Toland AE, Topka S, Trainer AH, Tung N, van Asperen CJ, van der Hout AH, van der Kolk LE, van der Luijt RB, Van Heetvelde M, Varesco L, Varon-Mateeva R, Vega A, Villarreal-Garza C, von Wachenfeldt A, Walker L, Wang-Gohrke S, Wappenschmidt B, Weber BHF, Yannoukakos D, Yoon SY, Zanzottera C, Zidan J, Zorn KK, Hutten Selkirk CG, Hulick PJ, Chenevix-Trench G, Spurdle AB, Antoniou AC, Nathanson KL.
- Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.** Hum Mutat. 2018 May;39(5):593-620. doi: 10.1002/humu.23406. Epub 2018 Mar 12. PMID: 29446198
53. Rhyasen GW, Yao Y, Zhang J, Dulak A, Castriotta L, Jacques K, Zhao W, Gharahdaghi F, Hattersley MM, Lyne PD, Clark E, Zinda M, Fawell SE, Mills GB, Chen H. **BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.** PLoS One. 2018 Jul 23;13(7):e0200826. doi: 10.1371/journal.pone.0200826. eCollection 2018. PMID: 30036377
54. Richardson DL, Coleman RL, Sill MW. **Paclitaxel and Pazopanib in Ovarian Cancer-Reply.** JAMA Oncol. 2018 Sep 1;4(9):1299. doi: 10.1001/jamaoncol.2018.1712. PMID: 29978183 No abstract available.
55. Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. **Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.** JAMA Oncol. 2018 Feb 1;4(2):196-202. doi: 10.1001/jamaoncol.2017.4218. PMID: 29242937 Clinical Trial.
56. Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. **Stress effects on FosB and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.** J Biol Chem. 2018 Jun 29;293(26):10041. doi: 10.1074/jbc.AAC118.004299. PMID: 29959278 No abstract available.
57. Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G. **ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.** Nat Med. 2018 May;24(5):556-562. doi: 10.1038/s41591-018-0012-z. Epub 2018 May 7. PMID: 29736026
58. Simpkins F, Jang K, Yoon H, Hew KE, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM. **Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth**

- and Targets Tumor Initiating Stem-Like Cells.** Clin Cancer Res. 2018 Oct 1;24(19):4874-4886. doi: 10.1158/1078-0432.CCR-17-3697. Epub 2018 Jun 29. PMID: 29959144
59. Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. **BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.** Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019. PMID: 29533782
60. Sutton MN, Yang H, Huang GY, Fu C, Pontikos M, Wang Y, Mao W, Pang L, Yang M, Liu J, Parker-Thornburg J, Lu Z, Bast RC Jr. **RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells.** Autophagy. 2018;14(4):637-653. doi: 10.1080/15548627.2018.1427022. Epub 2018 Mar 21. PMID: 29368982
61. Taylor JS, He W, Harrison R, Zhao H, Sun CC, Lu KH, Giordano SH, Meyer LA. **Disparities in treatment and survival among elderly ovarian cancer patients.** Gynecol Oncol. 2018 Nov;151(2):269-274. doi: 10.1016/j.ygyno.2018.08.041. Epub 2018 Sep 22. PMID: 30253875
62. Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, Zhang Z, Wang YV, Huang L, Yuan M, Xia W, Chang WC, Huang WC, Liu CL, Chang YC, Liu J, Wu Y, Jin VX, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung MC, Wei W. **Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.** Mol Cell. 2018 Jan 18;69(2):279-291.e5. doi: 10.1016/j.molcel.2017.12.024. PMID: 29351847
63. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC Jr. **Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.** Clin Cancer Res. 2018 Oct 15;24(20):5072-5084. doi: 10.1158/1078-0432.CCR-18-0504. Epub 2018 Jul 3. PMID: 30084832
64. Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, Lu KH, Freedman RS, Birrer MJ, Wong KK, Mok SC. **ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression.** Cancers (Basel). 2018 Nov 22;10(12):464. doi: 10.3390/cancers10120464. PMID: 30469497
65. Zhang J, Dulak AM, Hattersley MM, Willis BS, Nikkilä J, Wang A, Lau A, Reimer C, Zinda M, Fawell SE, Mills GB, Chen H. **BRD4 facilitates replication stress-induced DNA damage response.** Oncogene. 2018 Jul;37(28):3763-3777. doi: 10.1038/s41388-018-0194-3. Epub 2018 Apr 11. PMID: 29636547
66. Zhang Y, Coletta AM, Allen PK, Parikh AM, Cox-Mattin M, Meyer LA, Sun CC, Basen-Engquist KM, Lu KH, Klopp AH. **Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer.** Int J Gynecol Cancer. 2018 Feb;28(2):285-292. doi: 10.1097/IGC.0000000000001165. PMID: 29303933
67. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC Jr, Sood AK, von Delft F, Ahmed AA. **Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.** Nat Commun. 2018 Feb 2;9(1):476. doi: 10.1038/s41467-017-02811-7. PMID: 29396402
68. Zibetti Dal Molin G, Abrahão CM, Coleman RL, Maluf FC. **Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.** Gynecol Oncol Res Pract. 2018 Aug 18;5:6. doi: 10.1186/s40661-018-0063-3. eCollection 2018. PMID: 30147940